Search form
Search
About us
Oxurion at a glance
A word from the CEO and Chairman
Our milestones
Our mission
Part of a global retina community
Our team
Partnerships
Venture projects
Global locations
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Other target diseases
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
THR-687 (pan RGD integrin antagonist)
Science team
Partnerships
Products
Jetrea
Investors
Shareholder Information
Share Price
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
News & Events
Latest news
Conferences & Events
Media contact
Reports & presentations
Contact
Perspectives
Menu
About us
Oxurion at a glance
A word from the CEO and Chairman
Our milestones
Our mission
Part of a global retina community
Our team
Partnerships
Venture projects
Global locations
Careers
Science
Unmet medical need
We focus on non-VEGF pathways
Back of the eye disorders
Back of the eye
Diabetic eye disease
Other target diseases
Symptomatic VMA/VMT
Pipeline
THR-149 (PKal Inhibitor)
THR-687 (pan RGD integrin antagonist)
Science team
Partnerships
Products
Jetrea
Investors
Shareholder Information
Share Price
Reports & presentations
Analyst Coverage
Conferences & Events
Financial calendar
Corporate governance
Investor relations contact
News & Events
Latest news
Conferences & Events
Media contact
Reports & presentations
Contact
Perspectives
Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye
THR-687 - Further readings
A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells.
Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.
Angiopoietin 2 induces astrocyte apoptosis via alphavbeta5-integrin signaling in diabetic retinopathy.
Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy.
Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation.
Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen.
Definition of two angiogenic pathways by distinct alpha v integrins.
Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR).
Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes.
Expression of integrins in human proliferative diabetic retinopathy membranes.
Immunolocalization of integrins in proliferative retinal membranes.
Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist.
Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells.
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity.
Integrins in angiogenesis and lymphangiogenesis.
Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis.
N-acetylglucosaminyltransferase V negatively regulates integrin alpha5beta1-mediated monocyte adhesion and transmigration through vascular endothelium.
Ocular Distribution and Pharmacodynamics of SF0166, a Topically Administered alphavbeta3 Integrin Antagonist, for the Treatment of Retinal Diseases.
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.
Pages
1
2
next ›
last »